Sustained-Release Corticosteroid Options

Mariana Cabrera, Steven Yeh, Thomas A. Albini

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis. Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA). Each has different physical characteristics and duration effect and has been approved for different indications. Herein we provide a summary of the current clinical knowledge regarding these implants.

Original languageEnglish (US)
Article number164692
JournalJournal of Ophthalmology
StatePublished - 2014
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Sustained-Release Corticosteroid Options'. Together they form a unique fingerprint.

Cite this